Clinical Trial

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase III, open-label, single-arm, multicenter study designed to evaluate the anti-tumor activity and safety of SY-5007 administered orally to participants with locally advanced or metastatic RET-positive NSCLC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-04; most recent amendment 2026-06-15.
Status change: Recruiting → Active, Not Recruiting 2026-06-15
Trial Details
NCT Number NCT06031558
Lead Sponsor Shouyao Holdings (Beijing) Co. LTD
Conditions Non-Small Cell Lung Cancer
Enrollment 120 participants
Start Date 2023-10-31
Primary Completion 2025-04-10 (estimated)
Study Completion 2026-06-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-16